Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Trial Profile

Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Luminespib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Oct 2018 Final results published in the Annals of Oncology
    • 31 Aug 2018 Biomarkers information updated
    • 18 Oct 2017 Primary endpoint (Overall Response Rate to AUY922) has been met, as per results presented at the 18th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top